Drug recall · December 31, 2014
Dacarbazine recall
Why: Discoloration: Reconstituted solution may appear pink instead of colorless to pale yellow when stored per the labeled conditions.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Dacarbazine, Injection, USP, 200mg, vials packaged in individual cartons, Rx only, Manufactured by Hospira Australia 1 Lexia Place, Mulgrave, Victoria Australia 3170. NDC 61703-327-22.
- Lots / codes
Lot #: B032223AA; Exp: July 2016
- Quantity
- 3,306 vials
- Company
- Hospira Inc., Lake Forest, IL
- Distribution
- Nationwide
- Initiated
- November 25, 2014 · Voluntary: Firm initiated
- Classified
- December 22, 2014
- Reported
- December 31, 2014
- Ended
- December 15, 2016
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Dacarbazine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.